Hemab Therapeutics (COAG) vs Replimune Group (REPL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Hemab Therapeutics is the larger company by market cap ($1.34 billion vs $1.24 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COAG | REPL |
|---|---|---|
| Share price | $28.70 | $13.20 |
| Market cap | $1.34B | $1.24B |
| 1-day change | +1.16% | -0.38% |
| YTD return | — | +35.80% |
| 1-year return | — | +183.87% |
| 5-year return | — | -56.22% |
| EPS (TTM) | $-4.33 | $-3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $55.42 | $16.33 |
| 52-week low | $23.00 | $1.50 |
| Distance from 52-week high | -48.21% | -19.17% |
| Average volume | 453.50K | 4.20M |
| Shares outstanding | 46.71M | 94.22M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
COAG vs REPL FAQ
Which is bigger, Hemab Therapeutics or Replimune Group?
Hemab Therapeutics (COAG) is larger, with a market capitalization of $1.34B compared with $1.24B for Replimune Group (REPL).
Are Hemab Therapeutics and Replimune Group in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.